Am J Psychiatry 155:1325-1331, October 1998
©Copyright 1998 American Psychiatric Association
Dopamine Transporter Occupancies in the Human Brain Induced by Therapeutic Doses of Oral Methylphenidate
Nora D. Volkow, M.D.,
Gene.-Jack Wang, M.D.,
Joanna S. Fowler, Ph.D.,
Samuel J. Gatley, Ph.D.,
Jean Logan, Ph.D.,
Yu-Shin Ding, Ph.D.,
Robert Hitzemann, Ph.D., and
Naomi Pappas, M.S.
Objective:The therapeutic effects of methylphenidate in the treatment of attention deficit disorder have been attributed to its ability to increase the synaptic concentration of dopamine by blocking the dopamine transporters. However, the levels of dopamine transporter blockade achieved by therapeutic doses of methylphenidate are not known. This study measured, for the first time, dopamine transporter occupancy by orally administered methylphenidate in the human brain and its rate of uptake in the brain. Method:Positron emission tomography (PET) and [11C]cocaine were used to estimate dopamine transporter occupancies after different doses of oral methylphenidate in seven normal subjects (mean age=24 years, SD=7). In addition, the pharmacokinetics of oral methylphenidate were measured in the baboon brain through use of PET and [11C]methylphenidate administered through an orogastric tube.Results:At 120 minutes after administration, oral methylphenidate produced a dose-dependent blockade of dopamine transporter; means=12% (SD=4%) for 5 mg, 40% (SD=12%) for 10 mg, 54% (SD=5%) for 20 mg, 72% (SD=3%) for 40 mg, and 74% (SD=2%) for 60 mg. The estimated dose of oral methylphenidate required to block 50% of the dopamine transporter corresponded to 0.25 mg/kg. Oral methylphenidate did not reach peak concentration in brain until 60 minutes after its administration.Conclusions:Oral methylphenidate is very effective in blocking dopamine transporters, and at the weight-adjusted doses used therapeutically (0.3 to 0.6 mg/kg), it is likely to occupy more than 50% of the dopamine transporters. The time to reach peak brain uptake for oral methylphenidate in brain corresponds well with the reported time course to reach peak behavioral effects. Am J Psychiatry 1998; 155: 1325-1331
This article has been cited by other articles:
|
|
|
|
 
K. E. Shannon, C. Sauder, T. P. Beauchaine, and L. M. Gatzke-Kopp
Disrupted Effective Connectivity Between the Medial Frontal Cortex and the Caudate in Adolescent Boys With Externalizing Behavior Disorders
Criminal Justice and Behavior,
November 1, 2009;
36(11):
1141 - 1157.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow, J. S. Fowler, J. Logan, D. Alexoff, W. Zhu, F. Telang, G.-J. Wang, M. Jayne, J. M. Hooker, C. Wong, et al.
Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain: Clinical Implications
JAMA,
March 18, 2009;
301(11):
1148 - 1154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kim, M. A. Teylan, M. Baron, A. Sands, A. C. Nairn, and P. Greengard
Methylphenidate-induced dendritic spine formation and {Delta}FosB expression in nucleus accumbens
PNAS,
February 24, 2009;
106(8):
2915 - 2920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Cassaday, B. Finger, and R. Horsley
Methylphenidate and nicotine focus responding to an informative discrete CS over successive sessions of appetitive conditioning
J Psychopharmacol,
November 1, 2008;
22(8):
849 - 859.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. D. Mahon, B. R. Stephens, and A. S. Cole
Exercise Responses in Boys With Attention Deficit/Hyperactivity Disorder: Effects of Stimulant Medication
J Atten Disord,
September 1, 2008;
12(2):
170 - 176.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. M. Dodds, U. Muller, L. Clark, A. van Loon, R. Cools, and T. W. Robbins
Methylphenidate Has Differential Effects on Blood Oxygenation Level-Dependent Signal Related to Cognitive Subprocesses of Reversal Learning
J. Neurosci.,
June 4, 2008;
28(23):
5976 - 5982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow, G.-J. Wang, F. Telang, J. S. Fowler, J. Logan, M. Jayne, Y. Ma, K. Pradhan, and C. Wong
Profound Decreases in Dopamine Release in Striatum in Detoxified Alcoholics: Possible Orbitofrontal Involvement
J. Neurosci.,
November 14, 2007;
27(46):
12700 - 12706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Diamond
Consequences of Variations in Genes that affect Dopamine in Prefrontal Cortex
Cereb Cortex,
September 1, 2007;
17(suppl_1):
i161 - i170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S Goldfield, C. Lorello, and E. Doucet
Methylphenidate reduces energy intake and dietary fat intake in adults: a mechanism of reduced reinforcing value of food?
Am. J. Clinical Nutrition,
August 1, 2007;
86(2):
308 - 315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow, G.-J. Wang, J. Newcorn, F. Telang, M. V. Solanto, J. S. Fowler, J. Logan, Y. Ma, K. Schulz, K. Pradhan, et al.
Depressed Dopamine Activity in Caudate and Preliminary Evidence of Limbic Involvement in Adults With Attention-Deficit/Hyperactivity Disorder
Arch Gen Psychiatry,
August 1, 2007;
64(8):
932 - 940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Gray, M. Punsoni, N. E. Tabori, J. T. Melton, V. Fanslow, M. J. Ward, B. Zupan, D. Menzer, J. Rice, C. T. Drake, et al.
Methylphenidate Administration to Juvenile Rats Alters Brain Areas Involved in Cognition, Motivated Behaviors, Appetite, and Stress
J. Neurosci.,
July 4, 2007;
27(27):
7196 - 7207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.R. Horsley and H. J. Cassaday
Methylphenidate can reduce selectivity in associative learning in an aversive trace conditioning task
J Psychopharmacol,
July 1, 2007;
21(5):
492 - 500.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Nutt, K. Demyttenaere, Z. Janka, T. Aarre, M. Bourin, P. L. Canonico, J. L. Carrasco, and S. Stahl
The other face of depression, reduced positive affect: the role of catecholamines in causation and cure
J Psychopharmacol,
July 1, 2007;
21(5):
461 - 471.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D Devos, P Krystkowiak, F Clement, K Dujardin, O Cottencin, N Waucquier, K Ajebbar, B Thielemans, M Kroumova, A Duhamel, et al.
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease
J. Neurol. Neurosurg. Psychiatry,
May 1, 2007;
78(5):
470 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Nutt, J. H. Carter, and N. E. Carlson
Effects of Methylphenidate on Response to Oral Levodopa: A Double-blind Clinical Trial
Arch Neurol,
March 1, 2007;
64(3):
319 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al.
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology
J Psychopharmacol,
January 1, 2007;
21(1):
10 - 41.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Ashton, P. Gallagher, and B. Moore
The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder
J Psychopharmacol,
September 1, 2006;
20(5):
602 - 610.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. E. Wilens and J. Biederman
Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth
J Psychopharmacol,
July 1, 2006;
20(4):
580 - 588.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B.J. Casey and S. Durston, Ph.d.
From Behavior to Cognition to the Brain and Back: What Have We Learned From Functional Imaging Studies of Attention Deficit Hyperactivity Disorder?
Am J Psychiatry,
June 1, 2006;
163(6):
957 - 960.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Spencer, J. Biederman, P. E. Ciccone, B. K. Madras, D. D. Dougherty, A. A. Bonab, E. Livni, D. A. Parasrampuria, and A. J. Fischman
PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate
Am J Psychiatry,
March 1, 2006;
163(3):
387 - 395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sood, D. L. Barton, and C. L. Loprinzi
Use of methylphenidate in patients with cancer
American Journal of Hospice and Palliative Medicine,
January 1, 2006;
23(1):
35 - 40.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. L. Greenhill, S. Pliszka, M. K. Dulcan, W. Bernet, V. Arnold, J. Beitchman, R. S. Benson, O. Bukstein, J. Kinlan, J. McClellan, et al.
Practice Parameter for the Use of Stimulant Medications in the Treatment of Children, Adolescents, and Adults
Focus,
October 1, 2004;
2(4):
642 - 668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Wilens, S. V. Faraone, and J. Biederman
Attention-Deficit/Hyperactivity Disorder in Adults
JAMA,
August 4, 2004;
292(5):
619 - 623.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow, G.-J. Wang, J. S. Fowler, F. Telang, L. Maynard, J. Logan, S. J. Gatley, N. Pappas, C. Wong, P. Vaska, et al.
Evidence That Methylphenidate Enhances the Saliency of a Mathematical Task by Increasing Dopamine in the Human Brain
Am J Psychiatry,
July 1, 2004;
161(7):
1173 - 1180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow and J. M. Swanson
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Am J Psychiatry,
November 1, 2003;
160(11):
1909 - 1918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kuczenski and D. S. Segal
Exposure of Adolescent Rats to Oral Methylphenidate: Preferential Effects on Extracellular Norepinephrine and Absence of Sensitization and Cross-Sensitization to Methamphetamine
J. Neurosci.,
August 15, 2002;
22(16):
7264 - 7271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rozans, A. Dreisbach, J. J.L. Lertora, and M. J. Kahn
Palliative Uses of Methylphenidate in Patients With Cancer: A Review
J. Clin. Oncol.,
January 1, 2002;
20(1):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Bednarczyk
Functional Imaging for the Monitoring of Clinical Outcomes of Pharmacotherapy
Journal of Pharmacy Practice,
August 1, 2001;
14(4):
298 - 307.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. R. Gerasimov, M. Franceschi, N. D. Volkow, A. Gifford, S. J. Gatley, D. Marsteller, P. E. Molina, and S. L. Dewey
Comparison between Intraperitoneal and Oral Methylphenidate Administration: A Microdialysis and Locomotor Activity Study
J. Pharmacol. Exp. Ther.,
October 1, 2000;
295(1):
51 - 57.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. D. Volkow, S. J. Gatley, J. S. Fowler, G. Wang, J. Swanson;, R. R. Gainetdinov, W. C. Wetsel, and M. G. Caron;
Serotonin and the Therapeutic Effects of Ritalin
Science,
April 7, 2000;
288(5463):
11a - 11.
[Full Text]
|
|
|
|
|
|
|
R. Castaneda, R. Levy, M. Hardy, and M. Trujillo
Alcohol & Drug Abuse: Long-Acting Stimulants for the Treatment of Attention-Deficit Disorder in Cocaine-Dependent Adults
Psychiatr Serv,
February 1, 2000;
51(2):
169 - 171.
[Full Text]
[PDF]
|
|
|
|
|
|
|
ADHD: Unanswered Questions and Controversies
Journal Watch Psychiatry,
November 1, 1999;
1999(1101):
17 - 17.
[Full Text]
|
|
|
|
|
|
|
N. D. Volkow, J. S. Fowler, and G.-J. Wang
Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans
J Psychopharmacol,
July 1, 1999;
13(4):
337 - 345.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow, G.-J. Wang, J. S. Fowler, S. J. Gatley, J. Logan, Y.-S. Ding, S. L. Dewey, R. Hitzemann, A. N. Gifford, and N. R. Pappas
Blockade of Striatal Dopamine Transporters by Intravenous Methylphenidate Is Not Sufficient to Induce Self-Reports of "High"
J. Pharmacol. Exp. Ther.,
January 1, 1999;
288(1):
14 - 20.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
Rate and Level of Dopamine Blockade Achieved by MPH
Journal Watch Psychiatry,
December 1, 1998;
1998(1201):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
N. D. Volkow, G.-J. Wang, J. S. Fowler, J. Logan, M. Gerasimov, L. Maynard, Y.-S. Ding, S. J. Gatley, A. Gifford, and D. Franceschi
Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain
J. Neurosci.,
January 15, 2001;
21(2):
RC121 - RC121.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
